Icerguastat is under clinical development by InFlectis BioScience and currently in Phase I for Charcot-Marie-Tooth Disease Type I B. According to GlobalData, Phase I drugs for Charcot-Marie-Tooth Disease Type I B does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Icerguastat LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Icerguastat overview
Icerguastat (IFB-088) is under development for the treatment of orphan neurodegenerative diseases such as Charcot-marie-tooth disease type I A and type I B, and amyotrophic lateral sclerosis. It is a small molecule administered through oral route. The drug candidate acts by targeting the protein phosphatase 1 regulatory subunit 15A (PPP1R15A) and is being developed based on 3D-Screen technology.
It was also under development for the treatment of retinitis pigmentosa.
InFlectis BioScience overview
InFlectis BioScience (InFlectis) develops small molecules for the treatment of neuromuscular diseases. The company’s pipeline products include IFB-088 (icerguastat) inhibits PPP1R15A/PP1c phosphatase complex that treats amyotrophic lateral sclerosis (ALS) and Charcot-Marie-tooth disorder; IFB-048 treats multiple sclerosis (MS). InFlectis is headquartered in Nantes, Ile-de-France, France.
For a complete picture of Icerguastat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
